FREmedica is collaborating with an exciting research project called Bringing Evidence to Alternative Medicine (BEAM) to create a smartphone app for care plan progress tracking and program reminders.
The BEAM app provides the user with lifestyle notifications and reminders to wear their waveforce ONE.
BEAM members complete surveys such as the Fibromyalgia Impact Questionnaire and the Chalder Fatigue Scale over the course of the care plan.
The measures collected are analyzed to learn more about care plan effectiveness and compared against a control group of chronic Lyme sufferers not using the waveforce ONE frequency emitter. The data provided will help to better understand the syndrome called chronic Lyme.
Sign up to get the latest on sales, new releases and more …
© 2018 FREmedica. All rights reserved.
Any statements made by FREmedica about waveforce ONE were developed based on extensive review of document number 1300013 that was issued on July 29, 2016 by the U.S. Department of Health and Human Services Food and Drug Administration.
This document, entitled General Wellness: Policy for Low Risk Devices - Guidance for Industry and Food and Drug Administration Staff, was issued to “provide clarity to industry and FDA staff on the Centre for Devices and Radiological Health’s (CDRH’s) compliance policy for low risk products that promote a healthy lifestyle (general wellness products)”.
The waveforce ONE by FREmedica Technologies Inc. does not profess to treat or cure any disease or illness. Always seek professional medical advice for the diagnosis and treatment of any health condition.